Natco Pharma consolidated net profit dipped by 68 per cent to Rs 65.1 crore for the second quarter ended September 30, 2021.

The company had posted a consolidated net profit of Rs 203.9 crore in the July-September quarter of the previous fiscal.

The total revenue stood at Rs 415.2 crore for the second quarter against Rs 827.9 crore in the corresponding quarter of last year.

"The decline in revenue and profits compared to last year’s quarter is primarily due to a one-off contribution in prior period earnings,” the company said in its filing.

The company is poised for growth during the latter half of this financial year and confident of a strong rebound in business, the drug firm stated.

It noted that during the period under review, Lenalidomide and Everolimus were introduced in Canada and US, respectively.

"The revenues from these products will be realised in immediate quarters. The company is well prepared for its major launch of Lenalidomide in the US during Q4 of this financial year,” it added.